Cancer reports最新文献

{"title":"An Advanced IVB Lung Adenocarcinoma Patient With KRAS Mutations, Benefited From Camrelizumab Combined With Anti-Angiogenic Agents for Therapy: A Case Report","authors":"Li Wang,&nbsp;Jiaqi Wu,&nbsp;Ping Shao,&nbsp;Wuping Bao,&nbsp;Lin Mao,&nbsp;Zhendong Pan,&nbsp;Aihua Bao,&nbsp;Min Zhang,&nbsp;Zhenghua Wu,&nbsp;Guorong Fan","doi":"10.1002/cnr2.70186","DOIUrl":"https://doi.org/10.1002/cnr2.70186","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Although the presence of Kirsten murine sarcoma virus (KRAS) mutations predicts a failure of non-small cell carcinoma (NSCLC) patients to benefit from epidermal growth factor receptor (EGFR)—tyrosine kinase inhibitor (TKI) therapy it may be more sensitive to programmed combination therapy of programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors + anti-angiogenesis. Recent treatment guidelines and clinical studies related to adenocarcinoma in NSCLC have indicated that in patients with inoperable stage IV lung adenocarcinoma, immune checkpoint inhibitors in combination with anti-angiogenic drugs may exert a synergistic effect and significantly improve the efficacy of near-term treatment, but quantification and long-term follow-up of specific clinical indicators are still lacking. No previous cases of long-term good results with camrelizumab combined with anti-angiogenic agents for KRAS-mutated NSCLC have been described.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case</h3>\u0000 \u0000 <p>This manuscript reports a case of a patient with advanced NSCLC with pleural effusion and KRAS mutations treated poorly with conventional chemotherapy who had long-term (more than 18 months) benefit with immunotherapy combined with an anti-angiogenic inhibitor in Shanghai General Hospital. In this case, pharmaceutical care of the patient was carried out through therapeutic drug adjustment, compliance, efficacy assessment, and safety evaluation to provide a reference for improving the efficacy and safety of drug therapy in clinical practice. As of the last follow-up date (December 2023), overall survival was 27 months, and the patient is currently in good general condition with no significant complaints of discomfort.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>ICLs in combination with antiangiogenic therapy may be a therapeutic option for patients with KRAS mutations in advanced non-small cell lung cancer with good persistence.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 6","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70186","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144244951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"C1qtnf6 Expression as a Prognostic Biomarker and Therapeutic Target in Lung Adenocarcinoma: Implications for Immune Infiltration and Tumor Progression","authors":"Qincai Li,&nbsp;Hua Zhang,&nbsp;Hai Yun-Liu,&nbsp;Peifeng Zheng,&nbsp;Xiaogang Xu","doi":"10.1002/cnr2.70205","DOIUrl":"https://doi.org/10.1002/cnr2.70205","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The incidence and mortality of lung cancer are increasing every year, making it the primary cause of cancer-related fatalities globally. Upregulation of C1qtnf6 expression is observed in various human cancers. This study aimed to explore the function of C1qtnf6 in lung adenocarcinoma (LUAD) progression.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We used The Cancer Genome Atlas (TCGA) dataset to analyze data on lung cancer. The relationship between C1qtnf6 expression and treatment outcomes in patients with LUAD was evaluated using a Kaplan–Meier survival analysis. The receiver operating characteristic (ROC) curve was analyzed to ascertain the diagnostic value of C1qtnf6 in LUAD. Additionally, we performed a correlation analysis to investigate the association between the transcription of <i>C1qtnf6</i> and inflammation in LUAD. To create LUAD cell lines with reduced C1qtnf6 expression, <i>C1qtnf6</i> was knocked down, and several in vitro analyses were conducted to determine how <i>C1qtnf6</i> knockdown affected the proliferation and apoptosis of LUAD cells. Furthermore, the relationship between C1qtnf6 and Interleukin-10 (IL-10) was verified. Using the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis and Gene Ontology (GO) studies, we further examined the impact of <i>C1qtnf6</i> knockdown on the biological behavior of LUAD cells.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>TCGA dataset analysis revealed that C1qtnf6 expression was much higher in LUAD tissues than in the adjoining normal tissues. Correlation analysis revealed a relationship between C1qtnf6 expression and immune cell infiltration in LUAD. It has been demonstrated that C1qtnf6 expression is closely associated with the tumor immunological milieu, immune checkpoint blockade (ICB), and response to cisplatin treatment. In vitro tests revealed that <i>C1qtnf6</i> knockdown reduced IL-10 levels, accelerated apoptosis, and hindered the growth of LUAD cells, thus indicating a possible link between C1qtnf6 and inflammation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our results show that C1qtnf6 may be useful as a prognostic indicator for LUAD.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 6","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70205","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144244952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between Hormonal Factors and Risk of Lung and Upper Aerodigestive Tract Cancer in French Women: The E3N Prospective Cohort Study","authors":"Yawo E. Klu,&nbsp;Hélène Amazouz,&nbsp;Marianne Canonico,&nbsp;Pascal Guénel,&nbsp;Marina Kvaskoff,&nbsp;Gianluca Severi,&nbsp;Loredana Radoi,&nbsp;Aviane Auguste","doi":"10.1002/cnr2.70223","DOIUrl":"https://doi.org/10.1002/cnr2.70223","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Significant sex disparities exist in the incidence of lung and upper aero-digestive tract (UADT) cancers. Inverse relationships have often been observed between exposure to hormonal factors and these cancers. Data from epidemiological studies are still inconsistent.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>We investigated the association between hormonal factors and the risk of cancers of the lung and UADT in French women.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>E3N is a French prospective population-based cohort that recruited 98 995 women in 1990. We used a Cox proportional hazards regression models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) with age as the time scale. We also conducted a cluster analysis using the K-means method to assess distinct patterns of hormone exposure and the cancer risk associated with them.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>91 114 women were included (398 lung and 157 UADT). We highlighted 6 distinct exposure patterns of hormonal exposure, but no significant association was noted with cancer risk. Concerning individual factors, shorter menstrual cycles (≤ 24 days) were associated with a higher risk of developing female lung cancer even among never smokers (HR = 1.75, 95% CI = 1.01–3.01). Among never smokers, the risk of UADT was lower among women with at least 3 pregnancies compared to those with none (HR = 0.43, 95% CI = 0.20–0.91). Menarche under 12 years was associated with a non-significant increase in the risk of UADT cancer among never smokers (HR = 1.76, 95% CI = 0.95–3.26).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Menstrual cycle length was significantly associated with higher risk lung cancer, while UADT cancer was inversely associated with the number of pregnancies. Our findings are widely consistent with the commonly adopted hypothesis of oestrogen deficiency as a mechanism for UADT risk but not for lung cancer. While larger studies are needed to confirm these findings, our study is novel, particularly for UADT cancer since our study is one of the first longitudinal studies among never smokers.</p>\u0000 \u0000 <p><b>Trial Registration:</b> clinicaltrials.gov identifier: NCT03285230</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 6","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70223","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144244501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the Enhanced Liver Regeneration Patterns Following ALPPS Versus Selective Portal Vein Ligation in an Experimental Model","authors":"Dora Krisztina Tihanyi,&nbsp;Attila Szijarto,&nbsp;Andras Fulop,&nbsp;Decan Jiang,&nbsp;Lisa Ernst,&nbsp;Franziska Alexandra Meister,&nbsp;Christian Bleilevens,&nbsp;Alexander Theissen,&nbsp;Henrik Nienhüser,&nbsp;Deniz Uluk,&nbsp;Georg Lurje,&nbsp;Mehrabi Arianeb,&nbsp;Rene H. Tolba,&nbsp;Zoltan Czigany","doi":"10.1002/cnr2.70221","DOIUrl":"https://doi.org/10.1002/cnr2.70221","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Associating liver partition and portal vein ligation (PVL) for staged hepatectomy (ALPPS) and selective PV embolization (PVE) are important clinical strategies in liver surgery. Even though it has been demonstrated that ALPPS induces a more rapid and expressed hypertrophy than PVL/PVE, this phenomenon is still not well understood.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>In the present study, we aimed to characterize enhanced regeneration patterns in a rat model.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Male Wistar rats were used (<i>n</i> = 84; 220–250 g). Selective PVL and ALPPS were achieved using microsurgical techniques (RML-regenerating/LML-non-regenerating). Parameters of liver regeneration, microcirculation, hepatocyte morphology, hepatocellular injury, and activation status of certain protein kinases involved in liver regeneration were investigated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Right median lobe (RMLs) in the ALPPS group exhibited a more significant and rapid hypertrophy compared to PVL (regeneration ratio, 1.669 ± 0.155 vs. 1.980 ± 0.189, <i>p</i> = 0.009, PVL vs. ALPPS). ALPPS led to a more prominent hepatocellular injury. Hypertrophy was associated with increased microcirculation of the RML and a prominent increase of hepatocellular size (300.43 ± 31.92 μm² vs. 374.48 ± 58.34 μm², PVL vs. ALPPS) and morphology. There was an early pAkt/Akt activation after surgery which was significantly higher in ALPPS (5 ± 2 vs. 9.7 ± 3 RQ-fold-change, <i>p</i> = 0.0087, PVL vs. ALPPS).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Our results suggest that the enhanced regeneration in ALPPS is associated with characteristic changes in liver microcirculation, cell division, hepatocyte morphology, and activation of pAkt/Akt.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 6","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70221","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144206768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Crosstalk Between the Oncoproteins of High-Risk Human Papillomaviruses Types 16 and 18 in Colorectal Cancer Cell Models","authors":"Queenie Fernandes,&nbsp;Varghese Philipose Inchakalody,&nbsp;Sarra Mestiri,&nbsp;Takwa Bedhiafi,&nbsp;Shereena Hydrose,&nbsp;Sara S. Bashraheel,&nbsp;Maysaloun Merhi,&nbsp;Said Dermime,&nbsp;Ala-Eddin Al Moustafa","doi":"10.1002/cnr2.70197","DOIUrl":"https://doi.org/10.1002/cnr2.70197","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Colorectal cancer (CRC) represents a major fraction of the total cancer burden worldwide. It has been recently identified that various high-risk Human Papillomaviruses (HPVs) are present in human CRCs, where they play a critical role in the development and progression of the cancer.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>In this study, we explored the synergistic effect of the E6/E7 viral oncoproteins of the two most frequently observed HPV types (16 and 18) on KRAS and TP53 mutant CRC cell models.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We performed an experimental in vitro study utilizing lipofection to transfect KRAS and TP53 mutant CRC cell models (HCT 116 and HT-29 respectively) with E6/E7 oncoproteins of HPV types 16 and 18 individually and in combination. Subsequently, we assessed their synergistic effect on cell proliferation, invasion, migration, and survival. In addition, we also compared the protein expression patterns of key epithelial-mesenchymal transition (EMT) biomarkers like E-cadherin, fascin, and vimentin among transfected, co-transfected, and wild-type cells.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We found that the co-expression of E6/E7 of HPV types 16 and 18 enhanced cell proliferation, invasion, migration, and survival in both cell models. Interestingly, this was also accompanied by the deregulation of all three EMT biomarkers, E-cadherin, fascin, and vimentin. The synergistic effect of the viral oncoproteins in promoting cancer was more pronounced in TP53 mutant cells (HT-29) as compared to KRAS mutant cells (HCT 116). We also report that HPV type 18 can induce a greater and more sustained oncogenic outcome as compared to HPV type 16.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our data indicate that co-expression of the E6/E7 oncoproteins of HPV types 16 and 18 can enhance oncogenic processes in CRC, especially TP53 mutant CRC.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 6","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70197","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144213923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Study of the Role of the Tumor Microenvironment in Ovarian Cancer (MICO): A Prospective Monocentric Trial","authors":"Martina Arcieri,&nbsp;Eleonora Capezzali,&nbsp;Stefano Restaino,&nbsp;Sara Pregnolato,&nbsp;Laura Mariuzzi,&nbsp;Alessandro Mangogna,&nbsp;Maria Orsaria,&nbsp;Angelica Tulisso,&nbsp;Silvia Tonon,&nbsp;Maria De Martino,&nbsp;Miriam Isola,&nbsp;Lorenza Driul,&nbsp;Carlo Pucillo,&nbsp;Giovanni Scambia,&nbsp;Barbara Frossi,&nbsp;Giuseppe Vizzielli","doi":"10.1002/cnr2.70242","DOIUrl":"https://doi.org/10.1002/cnr2.70242","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Ovarian cancer (OC) is one of the most aggressive tumors requiring new therapeutic approaches. Immunotherapy represents an opportunity, but to date, OC patients do not appear to benefit from current protocols. A better understanding of the composition of the tumor microenvironment (TME), especially in its immune components, could unveil mechanisms of immune suppression in a useful way to predict response to therapies and develop new therapeutic approaches.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Method&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The MICO (tumor MICroenvironment of Ovarian cancer) study is a single-center observational study. Starting from peritoneal biopsy of high-grade serous ovarian carcinoma (HGSOC), the purpose of the MICO study is to generate tumor patient-derived organoid (PDOs) cultures and evaluate the concordance between in vitro platinum-based chemotherapy sensitivity and in vivo sensitivity. Simultaneously, we will characterize through multiparameter cytofluorimetric analysis the composition of the OC TME, focusing on B lymphocytes and mast cells whose roles in ovarian cancer remain controversial and underinvestigated. Furthermore, patients experiencing recurrence will be longitudinally followed to monitor changes in the TME composition and the responsiveness of PDOs to in vitro stimulation with drugs.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Discussion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The association between the composition of the TME, the reactivity of the PDOs, and patients' disease progression will be analyzed to identify whether specific subpopulations of tumor-infiltrating immune cells could be predictive factors of the disease outcomes. The comparison of molecular profiles, in vitro response to drugs, and clinical-pathological data will allow the definition of a pattern capable of predicting the response of the primary tumor for the identification of those patients who may benefit from specific treatment.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Strengths and Limitations&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The results of our study could help to better understand the OC behavior, may have implications for the development of effective immunotherapy and targeted pharmacological therapies for epithelial OC in a personalized medicine perspective. This will be a monocentric trial with an involvement of only 43 patients, so further studies will need to confirm our results.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Trial Registration&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The clinical trial has been registered at Clinical-Trials.gov with the i","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 6","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70242","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144206769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vulvar Adenocarcinoma With Pagetoid Spread: A Case Report","authors":"Kazuaki Nishimura,&nbsp;Seiji Kagami,&nbsp;Haruka Kajio,&nbsp;Tamaki Wada,&nbsp;Naoyuki Toki,&nbsp;Kiyoshi Yoshino","doi":"10.1002/cnr2.70241","DOIUrl":"https://doi.org/10.1002/cnr2.70241","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>In rare cases, cancer cells adjacent to the skin migrate intraepithelially and reach the epidermis, presenting a histological appearance similar to that of Paget's disease; this phenomenon is termed pagetoid spread. Herein, we report a case of vulvar adenocarcinoma with pagetoid spread, in which the primary lesion could not be identified outside the vulva.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case</h3>\u0000 \u0000 <p>An 84-year-old woman, presented with a 5-cm tumor in the right vulva. Histopathological examination revealed atypical Paget cells. Immunohistochemical examination revealed that the cells were positive for CK20 and CK7 and negative for CDX2 and GCDFP15. Thus, it was determined that the tumor was not a primary extramammary Paget's disease, but a secondary extramammary Paget's disease with pagetoid spread. There were no masses in the anus, rectum, urinary tract, or vagina. Computed tomography scan revealed a right vulvar tumor and lymph node enlargement around the abdominal aorta, and the tumor was diagnosed as lymph node metastasis of vulvar adenocarcinoma associated with extramammary Paget's disease.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>We report a rare case of vulvar adenocarcinoma with pagetoid spread.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 6","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70241","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144206809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Selenium Nanoparticles in Cancer Therapy: Unveiling Cytotoxic Mechanisms and Therapeutic Potential","authors":"Sumaira Anjum,&nbsp;Mariam Hashim,&nbsp;Maham Imran,&nbsp;Sundus Babur,&nbsp;Sanniah Adnan,&nbsp;Christophe Hano,&nbsp;Wisam Nabeel Ibrahim","doi":"10.1002/cnr2.70210","DOIUrl":"https://doi.org/10.1002/cnr2.70210","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Cancer represents a complex group of diseases characterized by abnormal cell proliferation, invasion, and metastasis. These features pose significant challenges to conventional therapeutic approaches, necessitating the development of more targeted and effective treatment strategies.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This review aims to explore the potential of selenium nanoparticles (SeNPs) as a novel therapeutic tool in cancer treatment, emphasizing their cytotoxic mechanisms and advantages over conventional therapies and other nanoparticles.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The review synthesizes findings from recent studies investigating the therapeutic properties of SeNPs in cancer models. Emphasis is placed on their ability to selectively target malignant cells, modulate redox status, and influence tumor-associated cellular processes such as autophagy and microRNA regulation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>SeNPs demonstrate intrinsic antioxidant properties that counteract oxidative stress commonly observed in cancer cells. They modulate critical cellular pathways and exhibit selective toxicity, damaging cancer cells while sparing healthy tissues. Additionally, their biocompatibility and capacity to deliver therapeutic agents contribute to improved safety and efficacy compared to other nanoparticle platforms.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Selenium nanoparticles hold significant promise as a next-generation cancer treatment modality. Their dual function—serving as both therapeutic agents and drug delivery vehicles—positions them as a powerful tool in precision oncology. By minimizing off-target effects and enhancing targeted drug delivery, SeNPs have the potential to advance the landscape of cancer theragnostics.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 6","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70210","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144190953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes of Microbiome in Human Papillomavirus Infection and Cervical Cancer: A Systematic Review and Meta-Analysis","authors":"Wei Zhang,&nbsp;Yan Ge,&nbsp;Lihe Yao,&nbsp;Qingchun Yan,&nbsp;Jiuju Wei,&nbsp;Yanfei Yin,&nbsp;Bin Liu","doi":"10.1002/cnr2.70246","DOIUrl":"https://doi.org/10.1002/cnr2.70246","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Objectives</h3>\u0000 \u0000 <p>We aimed to conduct a systematic review and meta-analysis of high-throughput sequencing studies to assess changes in microbiome alpha, beta diversity, and composition differences in patients with human papillomavirus (HPV) infection and cervical cancer.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The PubMed, Embase, Web of Science, and Cochrane Library databases were systematically searched to include original studies. The effect size estimates with a 95% confidence interval were combined using a random effects model. The meta-analysis was performed using the Stata MP16 software.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 64 studies were included, with a meta-analysis of the diversity index performed on a subset of seven studies. Microbial diversity of patients infected with HPV was observed to be significantly different from that of healthy controls (CHAO index: 95% CI 0.42, 5.03, <i>I</i>² = 99.18%, <i>p</i> &lt; 0.05). Subgroup analysis based on the sample collection region showed a significant difference between vaginal microbiota of the treatment group and control group, as measured by the Shannon index (95% CI 0.12, 0.97, <i>I</i>² = 67.09%, <i>p</i> &lt; 0.05). Further, subgroup analysis of samples sequenced with the primer pair for the V3–V4 region showed a statistically significant difference in alpha diversity (Shannon index: 95% CI 0.28, 0.72, <i>I</i>² = 0.00%, <i>p</i> &lt; 0.05) between treatment and control groups. The microbial diversity varied between patients with inferior cervical lesions (low-grade squamous intraepithelial lesion) and healthy controls (Shannon index: 95% CI 0.02, 0.58, <i>I</i>² = 0.00%, <i>p</i> &lt; 0.05). The bacterial marker genera differed at each cervical lesion stage. <i>Gardnerella</i> was prevalent during the HPV infection stage, but its proportion decreased after the occurrence of cervical lesions. In contrast, the proportions of <i>Prevotella</i>, <i>Porphyromonas</i>, and <i>Dialister</i> increased during the cervical cancer stages.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Patients with simple HPV infections frequently exhibit unstable microbial diversity and are influenced by various factors. The microbial environment continues to change after the occurrence of cervical lesions and is correlated with the severity of cervical lesions.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 6","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70246","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144190954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Neoadjuvant Chemotherapy With FLOT and Modified DCF Regimens in Nonmetastatic Gastric Adenocarcinoma","authors":"Mehdi Pourghasemian,&nbsp;Maryam Salimi,&nbsp;Effat Iranijam,&nbsp;Mohammad Negaresh","doi":"10.1002/cnr2.70247","DOIUrl":"https://doi.org/10.1002/cnr2.70247","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Backgrounds</h3>\u0000 \u0000 <p>Gastric adenocarcinoma is a common and severe type of malignancy. Treatment for advanced cases involves neoadjuvant chemotherapy before surgery and adjuvant chemotherapy if needed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>In this study, a comparison of two regimens of FLOT and mDCF has been conducted with regard to pathological and radiological response, as well as complications.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>The medical records of patients diagnosed with nonmetastatic gastric adenocarcinoma who randomly received therapy with either FLOT or mDCF regimens were studied. The two groups were compared regarding complications, radiological response based on RECIST Ver 1.1 criteria, the chance of successful gastrectomy, pathological response based on the TRG scale, and downstaging of the gastric adenocarcinoma following chemotherapy. In total, 90 patients were studied. 40 patients were treated with the mDCF regimen, while 50 received the FLOT regimen. The mDCF group experienced more side effects, and the FLOT group had higher response rates and a greater percentage of patients who underwent surgery with clear margins. Additionally, patients receiving FLOT treatment showed greater lymphatic involvement, tissue invasion, and disease stage improvement.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>According to the study, patients with limited local invasion gastric adenocarcinoma who are eligible for surgery may benefit more from the FLOT neoadjuvant regimen than the mDCF regimen. The FLOT regimen proves to be more efficient and has fewer complications.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 6","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70247","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144197444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}